Dynamic optimization of chronic migraine treatment: Current and future options

Neurology

Volumn 72, Issue 5 SUPPL. 1, 2009, Pages

  Mathew, Ninan T ^a  

^a Houston Headache Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; FLUOXETINE; GABAPENTIN; NADOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PLACEBO; PROPRANOLOL; SEROTONIN ANTAGONIST; TIZANIDINE; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROATE SEMISODIUM; VALPROIC ACID;

ALLODYNIA; ANOREXIA; ARTICLE; BODY POSTURE; BREATHING DISORDER; CHRONIC DAILY HEADACHE; CHRONIC TENSION HEADACHE; COGNITIVE DEFECT; COGNITIVE THERAPY; CONCENTRATION LOSS; COPING BEHAVIOR; COUNSELING; CRYOTHERAPY; DEPRESSION; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; ELECTROSTIMULATION THERAPY; EPISODIC MIGRAINE; EXERCISE; FATIGUE; FEEDBACK SYSTEM; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEART RIGHT LEFT SHUNT; HUMAN; HYPERTHERMIC THERAPY; IRREGULAR BREATHING; LOW DRUG DOSE; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; NAUSEA; NERVE STIMULATION; PARESTHESIA; PATENT FORAMEN OVALE; PATIENT COMPLIANCE; PHYSIOTHERAPIST; PRIORITY JOURNAL; PROPHYLAXIS; PTOSIS; RELAXATION TRAINING; SIDE EFFECT; SOMNOLENCE; STRESS MANAGEMENT; STRETCHING EXERCISE; TASTE DISORDER; TASTE PERVERSION; TINNITUS; TRANSFORMED MIGRAINE; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; ULTRASOUND THERAPY; UNSPECIFIED SIDE EFFECT; VAGUS NERVE STIMULATION; WEIGHT GAIN; WEIGHT REDUCTION; CLINICAL TRIAL; REVIEW;

CLINICAL TRIALS AS TOPIC; HUMANS; MIGRAINE DISORDERS;

EID: 62349130901     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181974821     Document Type: Article

References (31)

1. Silberstein SD. Chronic migraine: diagnosis and management strategy [case review]. Rev Neurol Dis 2004;1:155-160.
2. Saper JR, Dodick D, Gladstone JP. Management of chronic daily headache: challenges in clinical practice. Headache 2005;45(suppl 1):S74-S85.
3. Millea PJ, Brodie JJ. Tension-type headache. Am Fam Physician 2002;66:797-804.
4. Fontebasso M. Topiramate for migraine prophylaxis. Expert Opin Pharmacother 2007;8:2811-2823.
5. Bigal ME, Lipton RB. When migraine progresses: transformed or chronic migraine. Expert Rev Neurother 2006; 6:297-306. Review.
6. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293-307.
7. Saper JR, Lake AE III, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002;42:470-482.
8. Bigal ME, Krymchantowski AV. Emerging drugs for migraine prophylaxis and treatment. MedGenMed 2006;8: 1-16.
9. Mathew NT. The prophylactic treatment of chronic daily headache. Headache 2006;46:1552-1564.
10. Silberstein SD, Lipton RB, Dodick DW, et al. The Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007;47:170-180.
11. Spira PJ, Beran RG; Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003;61:1753-1759.
12. Saper JR, Silberstein SD, Lake AE III, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994;34:497-502.
13. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002;42:510-514.
14. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008;9:37-41.
15. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ; TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007;27:814-823.
16. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23:820-824.
17. Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008;48:201-209.
18. Menezes C, Rodrigues B, Magalhães E, Melo A. Botulinum toxin type A in refractory chronic migraine: an open-label trial. Arq Neuropsiquiatr 2007;65:596-598.
19. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD; BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005;45:315-324.
20. Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain 2006; 125:286-295.
21. Mathew NT, Kailasam J, Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008;48:194-200.
22. Silberstein SD, Stark SR, Lucas SM, Christie SN, DeGryse RE, Turkel CC; BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80:1126-1137.
23. Mathew NT. A double-blind comparison of botulinum toxin type A (BoNTA) and topiramate for the prophylactic treatment of transformed migraine headaches: a pilot study. Presented at the 12th Congress of the European Federation of Neurological Societies; August 23-26, 2008; Madrid, Spain.
24. Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008;48: 210-220.
25. Pascual J, Leira R, Láinez JM. Combined therapy for migraine prevention? Clinical experience with a β-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 2003;23:961-962.
26. Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand 2007;115:81-83.
27. Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson BW. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA 2001;285:2208-2215.
28. Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E. Transcatheter closure of patent foramen ovale: a new migraine treatment? J Interv Cardiol 2003;16:39-42.
29. Jasper J, Hayek S. Implanted occipital nerve stimulators. Pain Physician 2008;11:187-200. Review.
30. Lenaerts ME, Oommen KJ, Couch JR, Skaggs V. Can vagus nerve stimulation help migraine? Cephalalgia 2008; 28:392-395.
31. Antal A, Lang N, Boros K, Nitsche M, Siebner HR, Paulus W. Homeostatic metaplasticity of the motor cortex is altered during headache-free intervals in migraine with aura. Cereb Cortex 2008;18:2701-2705.